Gerwin Huls,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Dana A. Chitu,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Thomas Pabst,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Saskia K. Klein,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Georg Stussi,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Laimonas Griskevicius,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Peter J. M. Valk,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Jacqueline Cloos,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Arjan A. van de Loosdrecht,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Dimitri Breems,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Danielle van Lammeren-Venema,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Isabelle van Zeventer,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Rinske Boersma,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Mojca Jongen-Lavrencic,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Martin Fehr,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Mels Hoogendoorn,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Markus G. Manz,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Maaike Söhne,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Rien van Marwijk Kooy,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Dries Deeren,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Marjolein W. M. van der Poel,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Marie Cecile Legdeur,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Lidwine Tick,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Yves Chalandon,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Emanuele Ammatuna,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Sabine Blum,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Bob Löwenberg,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),Gert J. Ossenkoppele,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)

View Articletitled, Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Supplemental data

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Clinical Trials & Observations

Stephen T. Oh,Moshe Talpaz,Aaron T. Gerds,Vikas Gupta,Srdan Verstovsek,Ruben Mesa,Carole B. Miller,Candido E. Rivera,Angela G. Fleischman,Swati Goel,Mark L. Heaney,Casey O’Connell,Murat O. Arcasoy,Yafeng Zhang,Jun Kawashima,Tomas Ganz,Mark Kowalski,Carrie Baker Brachmann

View Articletitled, ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Supplemental data

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma
Clinical Trials & Observations

Wen-Kai Weng,Sally Arai,Andrew Rezvani,Laura Johnston,Robert Lowsky,David Miklos,Judith Shizuru,Lori Muffly,Everett Meyer,Robert S. Negrin,Erica Wang,Timothy Almazan,Lynn Million,Michael Khodadoust,Shufeng Li,Richard T. Hoppe,Youn H. Kim

View Articletitled, Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma

IMMUNOBIOLOGY AND IMMUNOTHERAPY

The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome

Iosifina P. Foskolou,Laura Barbieri,Aude Vernet,David Bargiela,Pedro P. Cunha,Pedro Velica,Eunyeong Suh,Sandra Pietsch,Rugile Matuleviciute,Helene Rundqvist,Dominick McIntyre,Ken G. C. Smith,Randall S. Johnson

View Articletitled, The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome

Supplemental data

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Kodandaram Pillarisetti,Gordon Powers,Leopoldo Luistro,Alexander Babich,Eric Baldwin,Yingzhe Li,Xiaochun Zhang,Mark Mendonça,Nate Majewski,Rupesh Nanjunda,Diana Chin,Kathryn Packman,Yusri Elsayed,Ricardo Attar,François Gaudet

View Articletitled, Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Supplemental data

LYMPHOID NEOPLASIA

Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death

Debora Soncini,Paola Minetto,Claudia Martinuzzi,Pamela Becherini,Valeria Fenu,Fabio Guolo,Katia Todoerti,Giovanni Calice,Paola Contini,Maurizio Miglino,Giulia Rivoli,Sara Aquino,Alida Dominietto,Antonia Cagnetta,Mario Passalacqua,Santina Bruzzone,Alessio Nencioni,Massimo Zucchetti,Tommaso Ceruti,Antonino Neri,Roberto M. Lemoli,Michele Cea

View Articletitled, Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death

Supplemental data

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
Clinical Trials & Observations

Stephen Booth,Hannah Plaschkes,Amy A. Kirkwood,Adam Gibb,Patrick Horgan,Claire Higham,Joanna M. Oladipo,Joe Browning,Usman Khan,Bing Tseu,Lucia Chen,John Willan,Julia Wolf,Arief Gunawan,Paul Fields,Tim Ebsworth,Robert Lown,Dominic Gordon-Walker,Nimish Shah,Kim M. Linton,Graham P. Collins,Jaimal Kothari,Catherine Hildyard,Toby A. Eyre

View Articletitled, Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma

Supplemental data

Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma

Neeraj Jain,Satishkumar Singh,Georgios Laliotis,Amber Hart,Elizabeth Muhowski,Kristyna Kupcova,Tereza Chrbolkova,Tamer Khashab,Sayan Mullick Chowdhury,Anuvrat Sircar,Fazal Shirazi,Ram Kumar Singh,Lapo Alinari,Jiangjiang Zhu,Ondrej Havranek,Philip Tsichlis,Jennifer Woyach,Robert Baiocchi,Felipe Samaniego,Lalit Sehgal

View Articletitled, Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma

Supplemental data

CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia

Anthony Quagliano,Anilkumar Gopalakrishnapillai,E. Anders Kolb,Sonali P. Barwe

View Articletitled, CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia

Supplemental data

Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice

Sanjay Rathod,Manda Ramsey,Fred D. Finkelman,Christian A. Fernandez

View Articletitled, Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice

Supplemental data

Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Daisuke Kaji,Yasunori Ota,Yasuharu Sato,Koji Nagafuji,Yasunori Ueda,Masataka Okamoto,Yasushi Terasaki,Naoko Tsuyama,Kosei Matsue,Tomohiro Kinoshita,Go Yamamoto,Shuichi Taniguchi,Shigeru Chiba,Koichi Ohshima,Koji Izutsu

View Articletitled, Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Supplemental data

Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models
Clinical Trials & Observations

Stefan Alig,Vindi Jurinovic,Mohammad Shahrokh Esfahani,Sarah Haebe,Verena Passerini,Johannes C. Hellmuth,Erik Gaitzsch,William Keay,Natyra Tahiri,Anna Zoellner,Andreas Rosenwald,Wolfram Klapper,Harald Stein,Alfred Feller,German Ott,Annette M. Staiger,Heike Horn,Martin L. Hansmann,Christiane Pott,Michael Unterhalt,Christian Schmidt,Martin Dreyling,Ash A. Alizadeh,Wolfgang Hiddemann,Eva Hoster,Oliver Weigert

View Articletitled, Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models

Supplemental data

MYELOID NEOPLASIA

Thioridazine requires calcium influx to induce MLL-AF6–rearranged AML cell death

Claudia Tregnago,Ambra Da Ros,Elena Porcù,Maddalena Benetton,Manuela Simonato,Luca Simula,Giulia Borella,Katia Polato,Sonia Minuzzo,Giulia Borile,Paola Cogo,Silvia Campello,Alessandro Massi,Romeo Romagnoli,Barbara Buldini,Franco Locatelli,Martina Pigazzi

View Articletitled, Thioridazine requires calcium influx to induce MLL-AF6–rearranged AML cell death

Supplemental data

JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F⁻ MPNs

Friederike Pastore,Aishwarya Krishnan,Henrik M. Hammarén,Olli Silvennoinen,Benedict Yan,Ross L. Levine

View Articletitled, JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F− MPNs

Supplemental data

PLATELETS AND THROMBOPOIESIS

Platelets function as an acute viral reservoir during HIV-1 infection by harboring virus and T-cell complex formation

Sydney R. Simpson,Meera V. Singh,Stephen Dewhurst,Giovanni Schifitto,Sanjay B. Maggirwar

View Articletitled, Platelets function as an acute viral reservoir during HIV-1 infection by harboring virus and T-cell complex formation

Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study

Jason R. Hodges,Shannon M. Phillips,Sarah Norell,Chinonyelum Nwosu,Hamda Khan,Lingzi Luo,Sherif M. Badawy,Allison King,Paula Tanabe,Marsha Treadwell,Lucia Rojas Smith,Cecelia Calhoun,Jane S. Hankins,Jerlym Porter

View Articletitled, Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study

Supplemental data

HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation

Scott A. Peslak,Eugene Khandros,Peng Huang,Xianjiang Lan,Carly L. Geronimo,Jeremy D. Grevet,Osheiza Abdulmalik,Zhe Zhang,Belinda M. Giardine,Cheryl A. Keller,Junwei Shi,Ross C. Hardison,Gerd A. Blobel

View Articletitled, HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation

Supplemental data

THROMBOSIS AND HEMOSTASIS

Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia

Allyson M. Pishko,Robert K. Andrews,Elizabeth E. Gardiner,Daniel S. Lefler,Adam Cuker

View Articletitled, Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia

Supplemental data

Interferon-β alleviates delayed tPA-induced adverse effects via modulation of MMP3/9 production in ischemic stroke

Ping-Chang Kuo,Wen-Tsan Weng,Barbara A. Scofield,Destin Furnas,Hallel C. Paraiso,Alexander J. Intriago,Kristopher D. Bosi,I-Chen Yu,Jui-Hung Yen

View Articletitled, Interferon-β alleviates delayed tPA-induced adverse effects via modulation of MMP3/9 production in ischemic stroke

Supplemental data

Cysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia

Moua Yang,Wei Li,Calvin Harberg,Wenjing Chen,Hong Yue,Renan B. Ferreira,Sarah L. Wynia-Smith,Kate S. Carroll,Jacek Zielonka,Robert Flaumenhaft,Roy L. Silverstein,Brian C. Smith

View Articletitled, Cysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia

Supplemental data

Omega-6 DPA and its 12-lipoxygenase–oxidized lipids regulate platelet reactivity in a nongenomic PPARα-dependent manner

Jennifer Yeung,Reheman Adili,Adriana Yamaguchi,Cody J. Freedman,Angela Chen,Ryan Shami,Aditi Das,Theodore R. Holman,Michael Holinstat

View Articletitled, Omega-6 DPA and its 12-lipoxygenase–oxidized lipids regulate platelet reactivity in a nongenomic PPARα-dependent manner

Supplemental data

TRANSFUSION MEDICINE

A novel algorithm comprehensively characterizes human RH genes using whole-genome sequencing data

Ti-Cheng Chang,Kelly M. Haupfear,Jing Yu,Evadnie Rampersaud,Vivien A. Sheehan,Jonathan M. Flanagan,Jane S. Hankins,Mitchell J. Weiss,Gang Wu,Sunitha Vege,Connie M. Westhoff,Stella T. Chou,Yan Zheng

View Articletitled, A novel algorithm comprehensively characterizes human RH genes using whole-genome sequencing data

Supplemental data

TRANSPLANTATION

Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation
Clinical Trials & Observations

Burak Kalin,Yvette van Norden,Michel van Gelder,Dimitri Breems,Johan Maertens,Mojca Jongen-Lavrencic,Annoek E. C. Broers,Eric Braakman,Tim Grob,Wendelien Zeijlemaker,Gert J. Ossenkoppele,Ellen Meijer,Jan J. Cornelissen

View Articletitled, Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation

Supplemental data

ERRATUM

Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295-3301.

View Articletitled, Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295-3301.

Cover Image

Cover Image

COVER FIGURE
Model of thioridazine mechanism inducing apoptosis selectively in MLL-AF6–rearranged acute myeloid leukemia. See the article by Tregnago et al.
Front Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

IDCH: is it now determined?

PETAL: a global view on R/R T-/NK-lymphoma treatment reality

A telemedicine triage model for infusion center–based management of adult sickle cell pain episodes

Loss of protein C vs protein S results in discrepant thrombotic phenotypes

Evolving racial/ethnic disparities in AML survival in the novel therapy era

Advertisement intended for health care professionals

Issue Archive

Table of Contents

EXCEPTIONAL CASE REPORTS

COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease Clinical Trials & Observations

Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia Clinical Trials & Observations

Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization Clinical Trials & Observations

STIMULUS REPORTS

Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source Clinical Trials & Observations

REVIEW ARTICLES

SYSTEMATIC REVIEW

CLINICAL TRIALS AND OBSERVATIONS

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS Clinical Trials & Observations

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial Clinical Trials & Observations

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma Clinical Trials & Observations

Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models Clinical Trials & Observations

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSFUSION MEDICINE

TRANSPLANTATION

Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation Clinical Trials & Observations

ERRATUM

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease
Clinical Trials & Observations

Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia
Clinical Trials & Observations

Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization
Clinical Trials & Observations

Stable HLA antibodies following sustained CD19⁺ cell depletion implicate a long-lived plasma cell source
Clinical Trials & Observations

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
Clinical Trials & Observations

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Clinical Trials & Observations

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma
Clinical Trials & Observations

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
Clinical Trials & Observations

Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models
Clinical Trials & Observations

Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation
Clinical Trials & Observations